novo nordisk ozempic shortage - Search News

Novo Nordisk’s stock is rallying

MarketWatch on MSN · 6h

Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

24/7 Wall St · 1d

HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was over. It said the Danish pharmaceutical had sufficient supply of its semaglutide therapies to meet current and future,

Wall Street Journal · 9h

Novo Nordisk Stock Rallies on Weight-Loss Retreat by Hims & Hers

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood about 17% lower at under $42.

US FDA, Wegovy and Ozempic

Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's weight-loss and diabetes treatments Wegovy and Ozempic from its shortage list,

The Wall Street Journal on MSN · 4d

FDA Declares Shortage of Novo Nordisk’s Wegovy, Ozempic Over

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and projected demand in the country, the Danish pharmaceutical company said.

CNN on MSN · 4d

Ozempic and Wegovy are no longer in shortage, FDA says

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

4don MSN

Novo’s Ozempic Shortage Is Declared Over, Hitting Copycats

Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...

3don MSN

FDA says Ozempic shortage is over, chilling boom in off-brand versions

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results